X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (595) 595
humans (523) 523
animals (444) 444
female (352) 352
index medicus (335) 335
tropanes - pharmacology (319) 319
rats (240) 240
middle aged (230) 230
pharmacology & pharmacy (215) 215
tropanes - administration & dosage (213) 213
tropanes (185) 185
adult (180) 180
aged (170) 170
neurosciences (159) 159
dose-response relationship, drug (147) 147
dopamine transporter (134) 134
dopamine (116) 116
tomography, emission-computed, single-photon (111) 111
tropanes - therapeutic use (108) 108
dopamine plasma membrane transport proteins - metabolism (105) 105
time factors (102) 102
pulmonary disease, chronic obstructive - drug therapy (93) 93
spect (93) 93
clinical neurology (91) 91
tropanes - pharmacokinetics (90) 90
mice (88) 88
serotonin antagonists - pharmacology (87) 87
brain (83) 83
rats, sprague-dawley (82) 82
psychiatry (80) 80
tropanes - adverse effects (79) 79
parkinson's disease (78) 78
brain - diagnostic imaging (77) 77
cocaine (75) 75
binding (74) 74
dopamine plasma membrane transport proteins (72) 72
parkinson disease - diagnostic imaging (72) 72
tropanes - metabolism (72) 72
brain - metabolism (71) 71
dopamine - metabolism (71) 71
tomography, emission-computed, single-photon - methods (70) 70
radiology, nuclear medicine & medical imaging (66) 66
corpus striatum - metabolism (64) 64
rats, wistar (62) 62
corpus striatum - diagnostic imaging (59) 59
radiopharmaceuticals (58) 58
administration, inhalation (57) 57
respiratory system (56) 56
analysis (55) 55
nerve tissue proteins (55) 55
cocaine - pharmacology (54) 54
treatment outcome (54) 54
tropane alkaloids (54) 54
serotonin (53) 53
membrane glycoproteins (51) 51
receptors (51) 51
muscarinic antagonists - administration & dosage (49) 49
parkinsons-disease (49) 49
membrane transport proteins (47) 47
obstructive pulmonary-disease (47) 47
iodine radioisotopes (45) 45
cocaine - analogs & derivatives (44) 44
copd (44) 44
tiotropium (44) 44
bronchodilator agents - administration & dosage (43) 43
motor activity - drug effects (43) 43
phenols (43) 43
pulmonary disease, chronic obstructive - physiopathology (43) 43
aclidinium bromide (42) 42
toxicology (42) 42
aged, 80 and over (41) 41
pet (41) 41
safety (41) 41
atropine - pharmacology (40) 40
behavior, animal - drug effects (40) 40
carrier proteins - metabolism (40) 40
lung diseases, obstructive (40) 40
tropanes - chemistry (40) 40
double-blind method (39) 39
biochemistry & molecular biology (38) 38
chronic obstructive pulmonary disease (38) 38
muscarinic antagonists - adverse effects (38) 38
parkinson disease - metabolism (38) 38
severity of illness index (38) 38
5-ht (37) 37
chemistry, medicinal (37) 37
rat (37) 37
article (35) 35
drug therapy, combination (35) 35
efficacy (35) 35
neurology (35) 35
positron-emission-tomography (35) 35
in vitro techniques (34) 34
bronchodilator agents - therapeutic use (33) 33
guinea pigs (33) 33
muscarinic antagonists - therapeutic use (33) 33
pharmacokinetics (33) 33
adolescent (32) 32
brain - drug effects (32) 32
diagnosis (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (907) 907
German (25) 25
Russian (18) 18
French (11) 11
Polish (8) 8
Dutch (6) 6
Japanese (2) 2
Bulgarian (1) 1
Chinese (1) 1
Czech (1) 1
Danish (1) 1
Hungarian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Respiratory research, ISSN 1465-9921, 2014, Volume 15, Issue 1, pp. 123 - 123
Background: Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic... 
Formoterol | Dyspnea | Health status | Lung function | Aclidinium | COPD | MODERATE | HYPERINFLATION | BRONCHODILATION | MAINTENANCE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TIOTROPIUM | BROMIDE | ACCORD COPD | FLUTICASONE | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | North America | Recovery of Function | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Bronchodilator Agents - adverse effects | Tropanes - administration & dosage | Pulmonary Disease, Chronic Obstructive - diagnosis | Tropanes - adverse effects | Dry Powder Inhalers | Double-Blind Method | Drug Administration Schedule | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Dyspnea - physiopathology | Lung - physiopathology | New Zealand | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Australia | Health Status | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Pharmaceutical industry | Medical research | Studies | Heart attacks | Laboratories | Smooth muscle | Chronic obstructive pulmonary disease | Drug therapy | Research
Journal Article
International Journal of COPD, ISSN 1176-9106, 05/2017, Volume 12, pp. 1565 - 1577
Journal Article
Current Opinion in Pulmonary Medicine, ISSN 1070-5287, 03/2018, Volume 24, Issue 2, pp. 130 - 137
PURPOSE OF REVIEWRecent updates to the GOLD guidelines emphasize the use of combination LABA and LAMA bronchodilators for patients with chronic obstructive... 
Long-Acting muscarinic antagonists | Chronic obstructive pulmonary disease | Long-Acting beta agonists | Bronchodilator | CO-SUSPENSION(TM) DELIVERY TECHNOLOGY | long-acting beta agonists | LUNG-FUNCTION | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL-FLUTICASONE | ONCE-DAILY TIOTROPIUM | ACLIDINIUM BROMIDE | TO-SEVERE COPD | RESPIRATORY SYSTEM | LONG-TERM SAFETY | PARALLEL-GROUP | DOUBLE-BLIND | bronchodilator | chronic obstructive pulmonary disease | long-acting muscarinic antagonists | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Indans - therapeutic use | Quinuclidines - therapeutic use | Tiotropium Bromide - administration & dosage | Quinolones - therapeutic use | Tiotropium Bromide - therapeutic use | Indans - administration & dosage | Formoterol Fumarate - therapeutic use | Benzoxazines - administration & dosage | Glycopyrrolate - therapeutic use | Administration, Inhalation | Tropanes - therapeutic use | Benzoxazines - therapeutic use | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Chlorobenzenes - therapeutic use | Delayed-Action Preparations | Drug Combinations | Practice Guidelines as Topic | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Safety and security measures | Research | Drug therapy | Bronchodilator agents
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2015, Volume 109, Issue 10, pp. 1305 - 1311
Abstract Aim of our study was to understand if the interaction between aclidinium and formoterol administered at therapeutic doses leads to a synergistic... 
Pulmonary/Respiratory | Formoterol | Dual bronchodilation | Translation research | Aclidinium | COPD | CARDIAC & CARDIOVASCULAR SYSTEMS | HUMAN ISOLATED BRONCHI | PHARMACOLOGICAL CHARACTERIZATION | OBSTRUCTIVE PULMONARY-DISEASE | SMOOTH-MUSCLE | IN-VITRO | RESPIRATORY SYSTEM | BROMIDE | AIRWAYS | GLYCOPYRRONIUM | DRUG-COMBINATION | Single-Blind Method | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Adrenergic beta-2 Receptor Agonists - pharmacology | Bronchi - drug effects | Dose-Response Relationship, Drug | Muscarinic Antagonists - pharmacology | Female | Drug Therapy, Combination | Tropanes - administration & dosage | Formoterol Fumarate - pharmacology | Translational Medical Research | Tropanes - pharmacology | Administration, Inhalation | Bronchodilator Agents - pharmacology | Cross-Over Studies | Drug Synergism | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Acetylcholine | College teachers | Analysis | Studies | Influence | Laboratories | Drug dosages | Rodents
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2009, Volume 52, Issue 16, pp. 5076 - 5092
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 125, pp. 39 - 48
Abstract Introduction Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg efficacy and safety was demonstrated in two 6-month Phase III studies (AUGMENT... 
Pulmonary/Respiratory | Formoterol | Clinical trial | Combination therapy | Aclidinium | COPD | MEDICATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PERSISTENCE | AGONISTS | MULTIPLE | TRIAL | REFILL ADHERENCE | ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE | RESPIRATORY SYSTEM | TIOTROPIUM | Forced Expiratory Volume - drug effects | Outcome Assessment (Health Care) | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Adrenergic beta-2 Receptor Agonists - pharmacology | Muscarinic Antagonists - pharmacology | Female | Drug Therapy, Combination | Tropanes - administration & dosage | Tropanes - adverse effects | Double-Blind Method | Formoterol Fumarate - pharmacology | Tropanes - pharmacology | Formoterol Fumarate - adverse effects | Administration, Inhalation | Bronchodilator Agents - pharmacology | Dyspnea - physiopathology | Disease Progression | Muscarinic Antagonists - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Health Status | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Care and treatment | Drug therapy, Combination | Urinary tract infections | Respiratory agents | Dosage and administration | Bronchodilation | Effectiveness | Compliance | Lung diseases | Smooth muscle | Rhinopharyngitis | Infections | Urinary tract | Disease control | Patients | Incidence | Laboratory tests | Respiratory tract | Randomization | Dyspnea | Obstructive lung disease | Respiratory tract diseases | Chronic obstructive pulmonary disease | Safety | Respiration | Drug dosages
Journal Article
Journal Article